Skip to main content
logo
Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
11.55
-0.63 (-5.17%)
Oct 28, 2026, 4:00 PM EDT - Market closed

Enanta Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Oct - Sep.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Revenue
65.2665.3267.6479.286.1697.07
Revenue Growth
0.70%-3.42%-14.61%-8.07%-11.24%-20.74%
Gross Profit
65.2665.3267.6479.286.1697.07
Operating Income
-58.73-85.35-121.69-137.21-123.84-109.57
Net Income
-63.23-81.89-116.05-133.82-121.76-79
Earnings Per Share
-2.34-3.84-5.48-6.38-5.91-3.92
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Cash & Investments
211.49188.86248.19369.91278.52352.42
Total Debt
182.04201.06226.06222.4426.696.84
Net Cash (Debt)
29.45-12.1922.13147.47251.83345.58
Net Cash Growth
---85.00%-41.44%-27.13%-15.65%
Net Cash Per Share
1.09-0.571.057.0312.2217.13

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Operating Cash Flow
-35.32-19.27-78.76-103.15-84.78-70
Capital Expenditures
-1.62-12.9-17.95-9.06-2.13-0.75
Free Cash Flow
-36.94-32.17-96.71-112.21-86.91-70.75
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-89.99%-130.66%-179.92%-173.23%-143.74%-112.88%
Pretax Margin
-96.74%-127.90%-174.15%-165.39%-141.82%-110.82%
Profit Margin
-96.89%-125.36%-171.58%-168.95%-141.31%-81.38%
FCF Margin
-56.61%-49.24%-142.99%-141.67%-100.87%-72.88%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Forward PE
-6.266.266.266.26105.09
PS Ratio
5.153.923.252.9712.4811.83